Ruxolitinib Cream + Vehicle Cream

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Jun 12, 2023 → Nov 4, 2025

NCT ID

NCT05764161

About Ruxolitinib Cream + Vehicle Cream

Ruxolitinib Cream + Vehicle Cream is a phase 3 stage product being developed by Incyte for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT05764161. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

1 of 6 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (5)

✅UpadacitinibAbbVieApproved

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄DupilumabSanofiPhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06804811	Phase 3	Recruiting	Nov 13, 2025	Dec 1, 2027	NonSegmental Vitiligo
NCT06959225	Phase 3	Recruiting	Jun 23, 2025	Jul 11, 2027	Hidradenitis Suppurativa
NCT06958211	Phase 3	Recruiting	Jun 12, 2025	Jul 11, 2027	Hidradenitis Suppurativa
NCT06548360	Phase 3	Recruiting	Jan 24, 2025	Mar 13, 2027	NonSegmental Vitiligo
NCT06238817	Phase 3	Completed	Apr 26, 2024	Oct 17, 2025	Atopic Dermatitis
NCT05764161	Phase 3	Completed	Jun 12, 2023	Nov 4, 2025	Prurigo Nodularis
NCT05755438	Phase 3	Completed	Mar 10, 2023	Aug 13, 2025	Prurigo
NCT05635838	Phase 2	Completed	Dec 7, 2022	Mar 14, 2024	Hidradenitis Suppurativa
NCT05593432	Phase 2	Completed	Nov 23, 2022	Feb 26, 2024	Cutaneous Lichen Planus
NCT05593445	Phase 2	Completed	Nov 18, 2022	Dec 21, 2023	Lichen Sclerosus
NCT04896385	Phase 2	Completed	Jun 23, 2021	Jul 10, 2023	Vitiligo
NCT03745638	Phase 3	Completed	Dec 20, 2018	Dec 1, 2020	Atopic Dermatitis
NCT03745651	Phase 3	Completed	Dec 20, 2018	Nov 9, 2020	Atopic Dermatitis
NCT03099304	Phase 2	Completed	Jun 7, 2017	Sep 8, 2021	Vitiligo

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25